Lake Street initiated coverage of Prenetics (PRE) with a Buy rating and $29 price target Having divested three non-core assets, ACT Genomics, Europa, and its remaining stake in Insighta, Prenetics has generated more than $150M in proceeds while removing businesses that contributed little profitability and added operational complexity while shifting from a multi-division diagnostics and healthcare services company to a focused consumer health platform centered on its IM8 nutrition brand, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRE:
- Prenetics soars on IM8-fueled earnings call
- Prenetics Launches $40 Million Buyback as IM8 Growth, Liquidity Bolster Valuation Case
- Prenetics authorizes $40M share repurchase program
- Prenetics Executives Boost Personal Share Purchases to $2.75 Million After Earnings
- Prenetics announces executive open market share purchases